Prof Naveed Sattar emphasized the financial implications of widespread access to Wegovy, stating that granting it to all eligible patients "would simply bankrupt the NHS." This highlights the economic realities behind obesity treatments in the UK, as the growing number of eligible patients has raised significant concern over funding and resource allocation within the healthcare system. The cost of treating obesity and its complications poses a critical challenge for the NHS, already facing immense budget pressures.
Ray expressed gratitude for receiving Wegovy, saying he felt "blessed" to be prescribed the treatment. His personal journey, along with losing 14kg in five months, showcases the potential effectiveness of the drug for weight management. However, the treatment comes with the caveat that he may need to be on it for life to maintain his weight loss, which emphasizes the long-term commitment involved in managing obesity effectively.
Collection
[
|
...
]